TARO लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 19:00):

Stats
आज की मात्रा	1 052.00
औसत मात्रा	43 979.00
बाजार मूल्य	1.59B
EPS	$0 ( 2024-01-25 )
अगली कमाई की तारीख	( $0.310 ) 2024-05-28
Last Dividend	$12.81 ( 2018-12-10 )
Next Dividend	$0 ( N/A )
P/E	34.60
ATR14	$0.0190 (0.04%)

Insider Trading

Date	Person	Action	Amount	type
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Sell	712 500	Warrant (right to buy)
2010-11-04	Sun Pharmaceutical Industries Ltd	Buy	5 159 765	Ordinary Shares
2010-11-01	Franklin Resources Inc	Sell	5 159 765	Ordinary Shares

INSIDER POWER
0.00
Last 84 transactions
Buy: 16 575 249 \| Sell: 25 681 902

मात्रा सहसंबंध

लंबा: 0.06 (neutral)

छोटा: -0.81 (strong negative)

Signal:(52.665) Neutral

Taro Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Taro Pharmaceutical सहसंबंध - मुद्रा/वस्त्र

0.69
( moderate )

0.88
( strong )

0.00
( neutral )

0.49
( neutral )

0.16
( neutral )

0.83
( strong )

Taro Pharmaceutical वित्तीय

Annual	2023
राजस्व:	$572.95M
सकल लाभ:	$268.32M (46.83 %)
EPS:	$0.680

FY	2023
राजस्व:	$572.95M
सकल लाभ:	$268.32M (46.83 %)
EPS:	$0.680

FY	2022
राजस्व:	$561.35M
सकल लाभ:	$293.12M (52.22 %)
EPS:	$1.550

FY	2021
राजस्व:	$548.97M
सकल लाभ:	$296.66M (54.04 %)
EPS:	$-10.12

Financial Reports:

No articles found.

Taro Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Taro Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.86 - average (62.51%) | Divividend Growth Potential Score: 2.19 - No dividend growth expected in the near future

Information

First Dividend	$12.81	2018-12-10
Last Dividend	$12.81	2018-12-10
Next Dividend	$0	N/A
Payout Date	2018-12-28
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$12.81	--
Avg. Dividend % Per Year	0.00%	--
Score	1.22	--
Div. Sustainability Score	5.86
Div.Growth Potential Score	2.19
Div. Directional Score	4.03	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.22

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2018	$12.81	12.40%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0748	1.500	8.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0211	1.200	9.30	10.00	[0 - 0.3]
returnOnEquityTTM	0.0261	1.500	-0.821	-1.231	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.60	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.03	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.022	1.500	5.43	8.15	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-2.55	1.000	-2.05	-2.05	[3 - 30]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.29	2.00	8.86	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.480	1.000	5.33	5.33	[0.2 - 0.8]
operatingProfitMarginTTM	0.0360	1.000	-1.280	-1.280	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.282	0.800	-1.451	-1.161	[0.5 - 2]
Total Score				5.86

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	34.87	1.000	6.58	0	[1 - 100]
returnOnEquityTTM	0.0261	2.50	-0.528	-1.231	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.29	2.00	9.24	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.769	1.500	-8.46	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.234	1.000	6.65	0	[0.1 - 0.5]
Total Score				2.19

Taro Pharmaceutical

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.